Malaria drug artesunate tested for rare lung condition
NCT ID NCT06872112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing whether artesunate, a drug used for malaria, is safe for people with pulmonary arterial hypertension (PAH). Fifteen adults with PAH will take increasing doses of artesunate capsules for 20 weeks. The main goal is to check for side effects, not yet to see if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- artesunate (oral capsules)
- What this could lead to
- If safe and effective, artesunate could become a new treatment option for pulmonary arterial hypertension, potentially improving blood flow and symptoms.
- What could go wrong
- This is a very early Phase 1 trial with only 15 people, focused on safety. It is too small to prove if artesunate actually helps PAH, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check